Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma

Rigshospitalet, Denmark40 enrolled

Overview

The purpose is to evaluate the activity and feasibility of a two drug regimen which is partly orally and partly intravenous in advanced pleural mesothelioma.

Chemotherapy with carboplatin i.v. day one in each cycle Vinorelbine i.v. day one, and orally day 8 in each cycle, repeat new cycle every 3 weeks. Total of 6 cycles. Endpoint is response rate, secondary endpoints survival and toxicity.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Malignant Pleural Mesothelioma

Interventions

Carboplatin and VinorelbineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically verified malignant pleural Mesothelioma * Age above 18 years * Performance status 0-2 Exclusion Criteria: * No previous chemotherapy * Normal renal, liver and bone marrow function

Locations (1)

Dept. Oncol., Rigshospitalet

Copenhagen, Copenhagen, Denmark

Outcomes

Primary Outcomes

Response

Secondary Outcomes

Survival

Feasibility

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.